Simultaneous measurement of sirolimus and everolimus in whole blood by HPLC with ultraviolet detection.

References 1. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483:45–53. 2. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400–11. 3. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763–71. 4. Bristol-Myers Squibb Company and Otsuka America Pharmaceutical Inc. Abilify (aripiprazole) tablets prescribing information. http://www.abilify. com (accessed July 2005). 5. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004;44:179–87. 6. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004;37:243–65. 7. Perry PJ. Therapeutic drug monitoring of antipsychotics. Psychopharmacol Bull 2001;35:19–29. 8. Härtter S, Weigmann H, Hiemke C. Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. J Chromatogr B 2000;740:135–40. 9. Zernig G, De Wit H, Telser S, Nienhusmeier M, Wakonigg G, Sturm K, et al. Subjective effects of slow-release bupropion vs. caffeine as determined in a quasi-naturalistic setting. Pharmacology 2004;70:206–15. 10. Clinical and Laboratory Standards Institute (CLSI). Evaluation of precision performance of clinical chemistry devices. NCCLS/CLSI Document EP5–T2. Wayne, PA: CLSI, 1992. 11. Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [C]raclopride. Neuropsychopharmacology 2002;27: 248–59.